literature

HIV mutation literature information.

Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.

PMID: 21972264 2012 Journal of the International Association of Physicians in AIDS Care (Chicago, Ill.

Abstract: Nonnucleoside reverse transcriptase inhibitor-associated mutation frequencies noted were associated with notable resistance to either/both NVP and EFV (n = 40; 88.9%); K103N (n = 15; 33.3%); >=1 mutations associated with etravirine (ETR) failure (K101E, Y181C, and G190A; n =20; 44.4%); and >=2 notable NNRTI mutations (n = 12; 26.7%).

Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

PMID: 22067667 2012 Journal of acquired immune deficiency syndromes (1999)

Abstract: The absolute number of VFs with treatment-emergent NNRTI resistance-associated mutations (RAMs) was higher for rilpivirine (most commonly E138K or K101E) than efavirenz (most commonly K103N), but relative proportions were similar [63% (39 of 62) vs.

Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database.

PMID: 22209291 2012 Journal of clinical virology

Abstract: OBJECTIVE: Objective of our investigation was to determine the prevalence of mutations E138K, Y181I/V, and K101E/P before the approval of rilpivirine.

Abstract: RESULTS: The E138K, Y181I/V, and the K101E mutations were found in 0.4%, 0.9%, and 2.4% of the patients, respectively.

No increase of drug-resistant HIV type 1 prevalence among drug-naive individuals in Northern Vietnam.

PMID: 22264087 2012 AIDS research and human retroviruses

Abstract: Nonnucleoside reverse-transcriptase inhibitor resistance mutations were found in two (2.0%) of the 102 successfully analyzed cases (one case with the Y181C and one with the K101E).

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.

PMID: 22267476 2012 Antiviral therapy

Abstract: NNRTI mutations selected were V179I (5 patients), V179L (1), V179F (2), L100I (1), K103N (2), Y181C (3), K101E (1), K101R (1) and H221Y (1).

Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.

PMID: 22293461 2012 Antiviral therapy

Result: Of the five with resistance at enrollment, no NRTI resistance was observed, two had resistance to NNRTIs (K103N n=1; V106M, K103N n=1), two had protease resistance (M46I n=1, M46L n=1) and one had both protease and NNRTI resistance (M46V, K101E, G190A).

Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.

PMID: 22337292 2012 Journal of medical virology

Abstract: The most prevalent ETR RAMs observed were L100I, V90I, and K101E, with a prevalence of 16.4% (n = 9), 9.1% (n = 5), and 5.5% (n = 3), respectively.

Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010.

PMID: 22448246 2012 PloS one

Method: The following resistance mutations were scored: to nucleoside reverse transcriptase inhibitors (NRTIs): M41L, K65R, D67N/G/E, T69D/insertion, K70R/E, L74V/I, V75M/T/A/S, F77L, Y115F, F116Y, Q151M, M184V/I, L210W, T215Y/F/I/S/C/D/V/E, K219Q/EN/R

Table: K101E

Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP.

PMID: 22536497 2012 AIDS research and treatment

Introduction: Several of these mutations, particularly K101E/P and M230L, have been associated with significant resistance to multiple NNRTIs.

Discussion: covered the virus containing K101E/Y181C/G190A and other mutations could increase 893-fold resistance to NVP.

Discussion: found the prevalence rate of H221Y in isolates from patients failing NVP treatment was 10.3% and the mutation was included in the top 10 and 15 determinants for NVP and EFV resistance, respectively, ranking even above some classical NNRTI resistance mutations, such as K101E, V108I, and G190E.

Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City.

PMID: 22592583 2012 Journal of acquired immune deficiency syndromes (1999)

4Method: ARV resistance was defined by mutations at the following positions: M41L, A62V, K65R, D67N, T69ins, K70R, L74VI, Y115F, F116Y, Q151M, M184VI, T210W, T215YF and K219QE for Nucleoside Reverse Transcriptase Inhibitors (NRTI), L100I, K101EP, K103NS, V106AM

Browser Board

Co-occurred Entities

Filtrator